Table 1.
Patient characteristics
| Rituximab | Golimumab | All | |
|---|---|---|---|
| Patients, number | 748 | 1370 | 2118 |
| Age, years | 47.9 (13.1) | 51.2 (12.2) | 50.1 (12.6) |
| Disease duration, years | 0.9 (1.2) | 7.3 (8.1) | 5.1 (7.2) |
| Female, % | 81.2 | 81.8 | 81.5 |
| Rheumatoid factor, % positive | 87.4 | 75.4 | 79.7 |
| ACPAs, % positive | 86.0 | 73.6 | 78.0 |
| Health assessment questionnaire | 1.8 (0.7) | 1.5 (0.) | 1.6 (0.78) |
| DAS28-ESR | 7.1 (1.0) | 5.5 (1.0) | 6.3 (1.3) |
| DAS28-CRP | 5.7 (0.9) | 5.1 (1.0) | 5.3 (1.0) |
| SDAI | 49.6 (14.8) | 39.4 (14.6) | 43.0 (15.5) |
| CDAI | 46.4 (14.0) | 37.2 (13.7) | 40.5 (14.5) |
| Swollen joint count, 0–28 | 14.5 (6.4) | 10.6 (6.0) | 12.0 (6.4) |
| Tender joint count, 0–28 | 18.2 (7.1) | 14.5 (7.41) | 15.8 (7.5) |
| Pain, VAS in mm | 63.5 (22.3) | 63.0 (22.0) | 63.2 (22.1) |
| Patient global assessment, VAS in mm | 68.5 (21.5) | 60.2 (23.4) | 63.1 (23.1) |
| Evaluator global assessment, VAS in mm | 68.2 (17.8) | 60.7 (17.8) | 63.3 (18.2) |
| ESR, mm | 59.1 (29.5) | 41.0 (26.3) | 50.7 (29.5) |
| CRP, mg/dl | 3.2 (2.9) | 2.1 (2.9) | 2.5 (2.9) |
| Radiographic score | 7.5 (11.2) | 25.8 (41.6) | 17.8 (33.3) |
ACPA antibody against citrullinated proteins, DAS28-ESR Disease Activity Score using 28 joint counts based on erythrocyte sedimentation rate, DAS28-CRP Disease Activity Score using 28 joint counts based on C-reactive protein, SDAI simplified disease activity index, CDAI clinical disease activity index, VAS visual analogue scale